Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Sensex Finishes Flat; Pharma & FMCG Stocks Fall
Tue, 4 Jul Closing

Indian share markets continued to swing between gains and losses in the afternoon session as market participants booked profit in recent outperformers.

At the closing bell, the BSE Sensex stood lower by 12 points, while the NSE Nifty finished down by 2 points. Meanwhile, the S&P BSE Mid Cap & the S&P BSE Small Cap finished down by 0.3% and 0.1% respectively. Losses were largely seen in pharma stocks, auto stocks and FMCG stocks.

Asian stock markets finished broadly lower today with shares in Hong Kong leading the region. The Hang Seng is down 1.53% while China's Shanghai Composite is off 0.41% and Japan's Nikkei 225 is lower by 0.12%. European markets are lower today with shares in France off the most. The CAC 40 is down 0.19% while Germany's DAX is off 0.18% and London's FTSE 100 is lower by 0.07%.

The rupee was trading at Rs 64.81 against the US$ in the afternoon session. Oil prices were trading at US$ 46.95 at the time of writing.

To increase foreign capital inflows in the country, the Reserve Bank of India (RBI) has increased the foreign portfolio investor (FPI) investment limit in Central Government Securities (G-secs) as well as in State Development Loans (SDLs) for the quarter July-September 2017, which will be effective from July 4, 2017.

According to the RBI's notification, the limit for investment by FPIs in G-secs will move up to Rs 2,420 billion from earlier Rs 2,310 billion, while in SDLs, the limit will go up to Rs 331 billion from Rs 270 billion. Hence, the total limit for FPIs will increase to Rs 2,751 billion from Rs 2,580 billion.

Besides, future increases in the limit for FPI investment in G-secs will be allocated in the ratio of 75% for long-term category of FPIs & 25% for general category.

As per the RBI notification, the central bank has done away with the practice of transferring unutilised limits of long-term category to general category of FPIs. The revised limit comes in to force as per RBI's review of the medium-term framework with relation to investment of FPIs in government securities.

Rising Foreign Direct Investments Augurs Well for India

FDI plays an important role in the economic development of a country. It is a source of long term capital that helps build critical infrastructures in the economy. It also aids in technology knowledge transfers, fosters innovation and helps raise productivity too. In short, having a steady flow of FDI inflows would help India to achieve necessary investments that will help accelerate economic growth and development.

In news from pharma sector, ICRA in its latest report has said that the growth momentum of the Indian pharmaceutical industry is likely to witness moderation in the next three years, largely owing to slowdown in revenues from the United Sates, increasing competition and adoption of generics reaching a saturation level.

Apart from this, it also noted that increased regulatory scrutiny and consolidation of supply chain in the US market along with increased R&D expenses will also have an impact on profitability of Indian drug companies.

The rating agency has pointed out that the overall aggregate revenues of 21 leading players increased only by 7.4% in FY17 as compared to 10.1% posted in the previous fiscal year. For the period between FY18 to FY20, it noted that the Indian pharma sector is expected to surge at 7-10% after mid to high double-digit growth over the last five years.

The report further said that the continued regulatory interventions in domestic market are expected to put some pressure in near term though long-term growth prospects for domestic pharmaceutical market remain healthy given increasing penetration, accessibility and continued new launches.

Just Released: Multibagger Stocks Guide
(2017 Edition)

In this report, we reveal four proven strategies to picking multibagger stocks.

Well over a million copies of this report have already been claimed over the years.

Go ahead, grab your copy today. It's Free.

NO-SPAM PLEDGE - We will NEVER rent, sell, or give away your e-mail address to anyone for any reason. You can unsubscribe from The 5 Minute WrapUp with a few clicks. Please read our Privacy Policy & Terms Of Use.

Pharma stocks finished in red with Natco Pharma share price and Divi's Lab share price leading the losses.

Meanwhile, IDFC share price finished the trading day on a firm note (up 1.2%) after it was reported that the company is planning to raise Rs 100 billion by issuing debt securities on private placement basis for which it will seek its shareholders' approval.

The company is eyeing to raise funds as it needs money to augment its business.

Also, JSW steel share price finished up by 1.4% as the company received shareholders' approval to raise over Rs 140 billion through various securities. The company has received consent for private placement of redeemable non- convertible debentures aggregating up to Rs 100 billion.

Besides, an approval was also given for issuance of non- convertible debentures with warrants for an amount not exceeding Rs 40 billion and/or issue of equity shares or fully, partly or optionally convertible debentures or any other convertible securities (other than warrants).

And here's a note from Profit Hunter:

Dr Reddy's Laboratory was among the top losers today in the Nifty 50 Index - down 2%. Let's have a look at its chart.

In our earlier note, we mentioned 2,750 as an important resistance level for the stock. Few days back, the stock formed a bullish divergence with the RSI indicator and rallied towards 2,750. But the stock found strong resistance near this level.

Today, the stock opened gap down and plunged 2%, reversing from the 2,750 resistance level.

So is the stock again ready post a new 52-week low?

Dr Reddy's down 2% for the Day
Dr Reddy's down 2% for the Day

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Sensex Finishes Flat; Pharma & FMCG Stocks Fall". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Jan 18, 2018 10:51 AM